Impact of USFDA 483s on Warning Letters

Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 753 International Journal of Medical and Pharmaceutical Research Online ISSN-2958-3683 | Print ISSN-2958-3675 Frequency: Bi-Monthly Available online on: https://ijmpr.in/ Review Article Impact of USFDA 483s on Warning Letters Yogesh Madhukar Binnar1,*, Dr Vinod Bhalla2 1Ph.D., Department of Chemistry of Singhania University, Pacheri Beri, Rajasthan, INDIA. 2Department of Microbiologist, University of Delhi, Delhi, INDIA. A B S T R A C T Corresponding Author: Mr. Yogesh Madhukar Binnar Ph.D., Department of Chemistry of Singhania University, Pacheri Beri, Rajasthan, INDIA. Received: 14-10-2025 Accepted: 16-11-2025 Available online: 26-11-2025 Objectives: This review looks at how United State Food and Drug Administration (USFDA) Form 483 observations are linked to warning letters, especially for Indian pharmaceutical companies. Methodology: The study focuses on drug manufacturers and uses data from inspections and warning letters between January 2023 and November 2024. It also compares some older data from 2018 to 2020 to see changes over time. The researcher studied several sources, including regulatory guidelines like USFDA, World Heald Organization (WHO), and European Union good manufacturing practices (EU GMP), to understand current good manufacturing practices (cGMP) and why companies fail to meet them. Results: The findings show that if company gets a Form 483 during an inspection, there is a more than 50% chance it may get warning letter later, especially if the company has failed to reply properly. Over the past two years, 20 Indian companies obtained letters. Out of these, 10 already had 483 observations earlier, while others failed their first inspection due to serious good manufacturing practices (GMP) problems. The review concludes that many warning letters happen because of poor GMP compliance and weak follow-up after past inspections. Future research can help companies avoid such issues by improving quality systems. This can lead to better product safety and help companies save time and money. Copyright © International Journal of Medical and Pharmaceutical Research Keywords: cGMP, Data Integrity, Form 483, No Action Indicated (NAI), Official Action Indicated (OAI), USFDA, Voluntary Action Indicated (VAI), Warning Letter. INTRODUCTION The Food and Drugs Administration (FDA) is responsible for ensuring that pharmaceutical, medical device, and food products meet the highest standards of safety, effectiveness, and conformity with regulatory requirements (DeBell & Chesney, 1982; Doherty, 1980). A critical tool used by the USFDA during inspections is FDA Form 483, which is issued when inspectors identify conditions or practices that may violate federal regulations, particularly those associated with Current Good Manufacturing Practices (cGMP) (FDA Form 483 FAQ, n.d.; USFDA 21 CFR Part 211, n.d.). The Form 483 serves as an official record of these inspectional observations and highlights areas where companies may be out of compliance (Kiernan, 1988; Pazhayatil et al., 2019). While receiving a Form 483 does not constitute an enforcement action, it indicates that the FDA has identified issues that require correction and may lead to regulatory consequences if not adequately addressed (Winchell, 2011; Patel, 2012). These observations may span several operational domains, including manufacturing processes, quality control, documentation systems, personnel training, and environmental controls (Ananth et al., 2018; Saini et al., 2022). USFDA 483 Observation Classifications The USFDA 483 findings are grouped into three main categories (Figure 1a) based on how serious the findings are and what action the FDA recommends (FDA Form 483 FAQ, n.d.). Official Action Indicated (OAI) This classification means that the FDA found serious regulatory issues site inspection, and further actions are expected. These actions could include a Warning Letter, product recalls, or even shutting down the facility (Church & Mahoney, Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 754 2009; Kiernan, 1988). OAI classifications are usually given when the FDA believes there is a significant risk regarding product quality or patient safety that requires immediate attention (Pazhayatil et al., 2019). No Action Indicated (NAI) The NAI classification means that the issues observed in the course of the inspection were not serious enough to require further regulatory steps from the FDA. It indicates that there were no major risks to product safety, and the problems can usually be fixed internally without the need for the agency to take additional steps. However, companies are still expected to correct any issues raised during the inspection (DeBell & Chesney, 1982; Doherty, 1980). Voluntary Action Indicated (VAI) The VAI classification means that the FDA found some issues throughout the inspection but believes the company can fix them on its own without needing official action. The company is anticipated to take corrective steps and usually needs to submit a response explaining how they will correct the issues (Winchell, 2011; Patel, 2012). The classification of USFDA 483 observations plays a crucial role in determining the level of regulatory scrutiny a company will face. Warning Letter or additional enforcement actions are often issued based on the classification of observations. If the observations are not resolved in a timely and effective manner, it can result in serious impact on the company, such as delays in product approval, market withdrawal, or reputational damage (Ananth et al., 2018; Saini et al., 2022). Figure 1b shows the flow of USFDA inspection (USFDA Inspection Classification Database, n.d.). Figure 1a: Figure 1b: USFDA 483 Observation Category. Flow of USFDA Inspection. Regulatory Guidelines 21 Code of Federal Regulation (CFR) Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals, 21 CFR Part 210 cGMP in Manufacturing, Processing, Packing, or Holding of Drugs (USFDA, 2023). Various regulatory frameworks and guidelines govern data integrity in the pharmaceutical industry like WHO Technical Report Series 1033 - Annex 4: WHO Guideline on data integrity in 2021 (WHO, 2021), US FDA has established guidelines such as 21 CFR Part 11, which addresses electronic records and electronic signatures and also in Part 211 (211.68, 211.100 and 211.160, 211.180, 211.188, 211.194, and 212.60(g)) which include the requirement for data integrity (USFDA, 2023). This regulation outlines requirements for ensuring the accuracy, authenticity, and security of electronic data (USFDA, 2023). Pharmaceutical Inspection Co-operation Scheme (PIC/S GUIDANCE) on good practices for data management and integrity in regulated GMP/Good Documentation Practice (GDP), environments in July 2021 (PIC/S, 2021), European Commissions (EC) EudraLex Volume 4 has set requirement for documentation (European Commission, 2022). METHODOLOGY The researcher has reviewed a range of articles, USFDA Form 483 observations, and letters sent to pharmaceutical companies over the past two years (2023 and 2024) (USFDA, 2024, Form 483 Database; USFDA, 2024, Warning Letters Database). In addition, regulatory guidelines for cGMP compliance, such as those from WHO TRS, USFDA, and EU GMP, were examined (WHO, 2021, TRS 1033; USFDA, 2022, 21 CFR Parts 210–211; European Commission, 2020, EudraLex Volume 4). The researcher also explored proposed research-related websites to gather additional information and deepen their understanding of the subject matter, as well as to gain insight into the perspectives of other researchers. NAI No observation and hence compliance is not require VAI Observation and compliance report is require OAI Observation for cGMP Violation and regulatory action can be taken USFDA Inspectio n Observat ion in Form 483 OAI, VAI,NAI Compli ance Report Review by FDA officer Releasi ng of EIR Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 755 This study evaluates cGMP violations based on the US FDA Form 483 observations for the years 2024 and 2023 (USFDA, 2024, Form 483 Database), along with warning letters issued to Indian pharmaceutical companies from January 2023 to November 2024 (USFDA, 2024, Warning Letters Database). Data from the years 2018 to 2020 are included solely for comparative purposes (see Table 1) (USFDA, 2020, Form 483 Database). The analysis focuses on reviewing findings recorded in the 483 forms and warning letters within the pharmaceutical (only drug manufacturer) industry. Other sectors, such as medical devices and food, received warning letters; those are excluded from this study (refer to Figure 2) (USFDA, 2024, Warning Letters Database). Figure 2: Methodology Table 1: Number of 483 Form & Warning Letter Year 483 Form Warning Letter % of warning letter against 483 Observation 2024 147 8 5.44 2023 150 12 8.00 2020 134 14 10.45 2019 227 25 11.01 2018 198 9 4.55 Table 1 shows the number of companies having USFDA observation in form 483 & warning letters from the year 2018 to 2024 in India (USFDA, 2018 - 2024, Form 483 & Warning Letters Database). And Figure 3 shows Graphical presentation for 483 Form & warning letter FY 2018–2024. Figure 3: Graphical presentation for 483 Form & warning letter FY 2018 – 2024. 2021 and 2022 were covid pandemic situation, and hence audit was not conducted; however, some companies had warning letters which are not listed in the above-said table (USFDA, 2022, Warning Letters Database). Below Table No. 2 shows company name were received 483 observations and warning letters. Table 2: List of Companies received Warning letter and 483 Form. Warning Letter Issue Date Company Name 483 Form Received Yes No 03/28/2024 Kilitch Healthcare India Limited Yes 07/17/2024 Velocity Pharma LLC No 07/25/2023 Baxter Healthcare Corporation No 04/08/2024 Natco Pharma Limited Yes 07/20/2023 Medgel Private Limited Yes 11/06/2024 Unexo Lifesciences, Private Limited No Data comparising FY 2018 to 2024 evaluation of Warning Letter Analysis on number of 483 Observation 483 observation to Indian Pharma USFDA data Base 0 100 200 300 2024 2023 2020 2019 2018 Comparison of 483 form and Warning Letter FY 2018 - 2024 483 Form Warning Letter Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 756 02/01/2024 Madhu Instruments Private Limited Yes 11/17/2023 Cipla Limited Yes 04/10/2023 Champaklal Maganlal Homeo Pharmacy Private Limited No 08/03/2023 Suhan Aerosol No 08/03/2023 Orchid Lifesciences No 12/15/2023 Patcos Cosmetics Pvt. Ltd. No 07/28/2023 Intas Pharmaceuticals Limited Yes 03/27/2024 Vintage Chemical Inc. No 06/05/2023 Centaur Pharmaceuticals Private Ltd. Yes 07/25/2023 Centaur Pharmaceuticals Private Ltd. Yes 04/20/2023 Accra-Pac, Inc. dba Voyant Beauty No 05/11/2023 Remedy Repack, Inc. No 08/15/2024 Eugia Pharma Specialities Limited Yes 10/16/2023 Sun Pharmaceutical Industries Ltd. Yes 06/11/2024 ARG Laboratories, Inc. No Ethical Consideration This review relies solely on information already available in the public regulatory domain and does not include any form of human or animal involvement. Since no experimental work or personal data collection was carried out, formal ethical clearance was not required for this study. RESULTS The review of Tables 1, 2, and 3 indicates that companies receiving USFDA Form 483 observations during inspections face a greater than 50% likelihood of subsequently receiving a warning letter, depending on the adequacy of their compliance response. As shown in Figure 4, the proportion of Official Action Indicated (OAI) outcomes over the past five years remains significant, with nearly 10% of cases falling under OAI, suggesting the presence of major or critical deficiencies requiring corrective measures. TABLE 3: CATEGORIZATION OF 483 OBSERVATIONS FOR 2024-2018 YEAR. Year 483 Form No. of Drug Companies who received Warning Letter General % of Warning Letter against OAI Observation % of OAI against Total number of Observation OAI VAI NAI Total Number of Drug Companies 2024 15 89 43 147 8 53.33 10.20 2023 19 86 45 150 12 63.16 12.67 2020 13 82 39 134 14 107.69 9.70 2019 30 121 76 227 25 83.33 13.22 2018 18 108 72 198 9 50 9.09 Figure 4: % of OAI presentation FY 2018 – 2024. 15 19 13 30 18 147 150 134 227 198 10.20 12.67 9.70 13.22 9.09 0 50 100 150 200 250 2024 2023 2020 2019 2018 % of OAI againt total form 483 483 Form OAI Total % of OAI against Total number of Observation Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 757 In 2023–2024, a total of 20 pharmaceutical firms received warning letters. Among these, 10 companies had already been issued Form 483 observations in earlier inspections, while others received warning letters during their initial inspection due to serious GMP violations and quality-related risks. DISCUSSION The observed pattern demonstrates a strong relationship between Form 483 observations and subsequent enforcement actions. Companies with unresolved, repeated, or poorly addressed deficiencies are more likely to receive warning letters. The recurrence of OAI outcomes signals gaps in quality systems, documentation practices, and adherence to cGMP requirements. Moreover, several firms receiving warning letters during their first USFDA inspection highlight the persistence of systemic compliance weaknesses across parts of the pharmaceutical sector. These findings reinforce the need for proactive quality oversight, robust internal audits, and timely corrective and preventive actions. CONCLUSION Overall, the analysis suggests that most warning letters issued during the review period stemmed from GMP noncompliance and insufficient responses to earlier inspection findings. Continued research on the root causes of Form 483 observations and warning letters will support companies in strengthening their quality systems, preventing recurring deficiencies, and enhancing regulatory readiness. Such improvements will not only help reduce compliance risks but also contribute to better product quality and long-term economic advantages for the industry. SUMMARY The analysis shows that pharmaceutical companies receiving Form 483 observations have a strong chance of later receiving USFDA warning letters, especially when earlier deficiencies were not addressed effectively. A review of recent inspection data reveals a consistent number of OAI outcomes, indicating recurring major compliance gaps. In 2023– 2024, half of the companies that received warning letters had previously been issued Form 483 observations, while others failed their first inspection due to significant GMP violations. Overall, the findings highlight that many enforcement actions result from weak GMP adherence and inadequate corrective responses. Strengthening quality systems and improving follow-up practices can help companies avoid repeated observations, reduce regulatory risk, and enhance product quality and operational efficiency. ABBREVIATIONS CGMP: Current Good Manufacturing Practices; CFR: Code Of Federal Regulations; EC: European Commission; EU GMP: European Union Good Manufacturing Practices; FDA: Food And Drug Administration; FY: Financial Year; GDP: Good Documentation Practice; GMP: Good Manufacturing Practices; NAI: No Action Indicated; OAI: Official Action Indicated; PIC/S: Pharmaceutical Inspection Co-Operation Scheme; USFDA: United State Food And Drug Administration; VAI: Voluntary Action Indicated; WHO TRS: World Health Organization Technical Report Series ACKNOWLEDGEMENTS The author expresses sincere gratitude to the co-author for their unwavering support and meaningful input provided during the preparation and completion of this review. Conflict Of Interest: The authors report that they hold no financial or personal interests that could influence this research. Financial Support and Sponsorship: The authors confirm that the research received no external financial assistance. Consent For Publication: All ethical considerations were duly addressed by the author and co-author. Since the study relied solely on open-access information from the USFDA database, no individual consent was required. Availability Of Data and Materials: All data relevant to this study are included in the manuscript. Additional underlying datasets are available from the author upon justified request. Author Contributions: The development of this review article was achieved through the committed efforts of the author and co-authors in collecting the data and performing its analysis and interpretation. REFERENCESS 1. Aarons, M. (1967). Factory Inspection. Food Drug Cosm. LJ, 22, 407. 2. Abraham, B., & Kumar, R. (2020). Dr. Reddy’s Laboratories Ltd: searching its glorious days. South Asian Journal of Business and Management Cases, 9(3), 359-374. 3. Abrol, D., John, R., & Guha, A. (2018). Economic Reforms and Pharmaceutical Manufacturing in India. Institute for Studies in Industrial Development (ISID), April, 1-78. 4. Adis, W. (2009). Analysis of FDS’s Risk Assessment Methodology at Pharmaceutical Manufacturing Site. Communications of the IIMA, 9(1), 1. 5. Adis, W. (2011). FDA’s quality systems methodology at pharmaceutical manufacturing sites. Communications of the IIMA, 11(1), 3. 6. Agarwal, V., Gupta, O., Priyadarshini, K., & Agrawal, S. A Failure of Regulatory Diligence: A Case Study of Ranbaxy Laboratories Ltd. Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 758 7. Ananth, L., Gurbani, N. K., Kumar, S., & Gujavarti, B. (2018). A retrospective study of Warning Letters issued by US FDA over 2015–2017. International Journal of Drug Regulatory Affairs (IJDRA), 6(2), 48-53. 8. Bai, H. K., Ahearn, J. D., & Bartlett, M. G. (2021). Over-the-counter drugs: regulatory analysis of warning letters between fiscal years 2015–2019. Therapeutic innovation & regulatory science, 55, 426-436. 9. Chatterjee, B., Dash, B., Shrestha, B., & Bhuyan, N. R. (2021). CURRENT SCENARIOS ON REGULATORY LANDSCAPE OF INDIAN PHARMACEUTICAL INDUSTRIES. 10. Chatterjee, S., Patel, H. K., & Sansgiry, S. S. (2012). An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims. Pharmacy practice, 10(4), 194. 11. Chingale, N. D., Walunj, S. D., Kikale, M. S., Devade, O. A., & Redasani, V. (2024). DOCUMENTATION ESSENTIALS IN THE PHARMACEUTICAL INDUSTRY: A REGULATORY PERSPECTIVE. 12. Church, R., & Mahoney, S. (2009). Trends in FDA good manufacturing practice warning letters. RAJ Pharma, 20, 433-435. 13. DeBell, L. E., & Chesney, D. L. (1982). The FDA Inspections Process. Food, Drug, Cosmetic Law Journal, 37(2), 244-249. 14. Deshpande, P., Agawane, R., Tatikola, S. C., & Vasantharaju, S. G. (2020). US FDA Warning Letters of CAPA Violations: A Review. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 7(2), 85-92. 15. Doherty, G. M. (1980). The Inspections Process. Food Drug Cosm. LJ, 35, 555. 16. Durá, M., Leal, F., Sánchez-García, Á., Sáez, C., García-Gómez, J. M., Chis, A. E., & González-Vélez, H. (2023). Blockchain for data originality in pharma manufacturing. Journal of Pharmaceutical Innovation, 18(4), 1745-1763. 17. EMA’s Guidance on Data Integrity, Available Form: https://www.ipa-india.org/wpcontent/uploads/2023/03/p201714.pdf 18. FDA Form 483 Frequently Asked Questions. Available Form: https://www.fda.gov/inspections-complianceenforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions 19. Frank, M. R. (1991). FDA Inspections: A Practical Corporate Response. Food Drug Cosm. LJ, 46, 71. 20. Gowtham, V., Ashok, K., Gupta, N., Gangadharappa, H., Aswani, N., & Shivakumar, H. (2011). Documentation in the process of obtaining US FDA approval for a tablet manufacturing industry. Journal of Pharmacy Research, 4(11), 3989-3991. 21. Hile, J. P. (1974). Food and Drug Administration Inspections-A New Approach. Food Drug Cosm. LJ, 29, 101. 22. Jain, S. K., & Jain, R. K. (2017). Investigations and CAPA: quality system for continual improvement in pharmaceutical industry. Int J Res Pharm Pharm Sci., 2, 47-54. 23. Jain, S. K., & Jain, R. K. (2018). Review of FDA warning letters to pharmaceuticals: Cause and effect analysis. Research Journal of Pharmacy and Technology, 11(7), 3219-3226. 24. Jain, S. K., & Jain, R. K. (2020). Avoiding warning letters in pharmaceutical industry: A qualitative study in the Indian context. The Pharma Innovation, 9(6), 18-24. 25. Jaiswal, H., Muddukrishna, B. S., & Kulyadi, G. P. (2020). Data integrity violations: A challenge to the pharmaceutical industry. Quality assurance, 5, 16. 26. James, R., Das, S., Kumari, A., Rekdal, M., Kulyadi, G. P., & Sathyanarayana, M. B. (2021). A Recent Regulatory Update on Consequences of Data Integrity Issues and its Management in Pharmaceutical Scenario. Indian Journal of Pharmaceutical Education and Research, 55(2), S616-S622. 27. Kamal, R., Diksha, Paul, P., & Awasthi, A. (2024). Steering through Regulatory Currents: The Journey of India’s Pharma Industry with the USFDA. Applied Drug Research, Clinical Trials and Regulatory Affairs, 10(1), E26673371310378. 28. Kamaraj, R., & Kumar, T. S. (2022). A Cross-Sectional Analysis Of Data Integrity Related Usfda Warning Letters To Improve Compliance Status. Journal of Pharmaceutical Negative Results, 2318-2324. 29. Kavasidis, I., Lallas, E., Leligkou, H. C., Oikonomidis, G., Karydas, D., Gerogiannis, V. C., & Karageorgos, A. (2023). Deep Transformers for Computing and Predicting ALCOA+ Data Integrity Compliance in the Pharmaceutical Industry. Applied Sciences, 13(13), 7616. 30. Kiernan, R. D. (1988). Factory Inspection: Responding to an Issued FDA Form 483. Food Drug Cosm. LJ, 43, 699. 31. Kolekar, P. D., & Bhagwat, A. M. (2021). Good Documentation Practices: A Need of Pharmaceutical Industry. 32. Lavian, M., & Allen, P. W. (2002). Survival Guide to FDA Inspections. BioPharm International. 33. McDowall, R. D. (2019). Do You Understand the FDA’s Updated Approach to Pre-Approval Inspections?. 34. Merino, J Merino, J., Reyes, D., & Walia, G. REPRINT WITH PERMISSION ONLY.(2024). BioProcess International. 35. Patel, A. B., Jinja, B. K., Vyas, A. K. J., Patel, N. K., Patel, A. I., Sheth, D. B., & Shah, S. R. (2022). A Retrospective Study of Warning letters Issued by US FDA Over 2019-2021. Asian Journal of Pharmaceutical Research, 12(4), 295-301. 36. Patel, D. P., Kanaki, N., Movaliya, V., & Zaveri, M. (2023). Review on inspectional observation and warning letters. International Journal Of Drug Regulatory Affairs, 11(2), 64-67. 37. Patel, D. S. (2012). FDA Warning letter analysis: A Tool for GMP Compliance. International Journal of Pharmaceutical Sciences and Research, 3(12), 4592. Yogesh Madhukar Binnar et al. Impact of USFDA 483s on Warning Letters. Int. J Med. Pharm. Res., 6 (6): 753‐759, 2025 759 38. Pazhayatil, A. B., Sayeed, N., & Ingram, M. (2019). Lessons from FDA 483s and cGMP Inspection Data. Pharmaceutical Technology, 43(10). 39. Pazhayattil, A. B., Ingram, M., & Sayeed, N. A Quantitative Study of US FDA Inspection Data for Drug Manufacturing. 40. Pazhayattil, A., & Ingram, M. Key Post-Pandemic Trends In Global FDA Observations For Drug Facilities. 41. Poska, R., & Graham, B. (2009). FDA 483 Responses-Suggestions for Industry. Journal of Validation Technology, 15(2), 57. 42. Rathore, A. S., Li, Y., Chhabra, H., & Lohiya, A. (2023). FDA warning letters: a retrospective analysis of letters issued to pharmaceutical companies from 2010–2020. Journal of Pharmaceutical Innovation, 18(2), 665-674. 43. Saini, C., Miglani, A., Musyuni, P., & Aggarwal, G. (2022). Review of form 483s and warning letters to pharmaceutical manufacturers issued by USFDA. Journal of Generic Medicines, 18(1), 32-41. 44. Shah, Darshil B., Jignesh S. Shah, and Dilip G. Maheshwari. "Exploring the Data Integrity Ordinance in Pharmaceutical Domain." J Young Pharm 14.4 (2022): 377-381. 45. Shah, N. K. (2020). Financial Statement Analysis Through Ratio Analysis of Selected Pharmaceutical Companies. GAP Interdisciplinarities, 3(6), 321-331. 46. Shashikant, G. S., Chhabra, G., & Nayan, G. (2018). Handling of market complaints and recalls, review of FDA-483 form. Asian Journal of Pharmaceutical Research and Development, 6(3), 55-59. 47. Tripathy, S., Pandey, P., Mohanty, S., Murthy, P. N., & Sengodan Guruswamy, V. (2017). Audit and Compliance-Bird's Eye on Current Indian Pharmaceutical Environment. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 4(2), 114-119. 48. ul Alam, A. M. (2024). Analyzing FDA form 483 data of 2023: Identifying trends and areas of concern in regulatory compliance. Journal of Pharmaceutical and Biological Sciences, 12(1), 3-7. 49. Unger, B. (2014). An Analysis Of FDA FY2016 Drug GMP Warning Letters. URL: https://www.pharmaceuticalonline.com/doc/an-analysisof-fda-fy-drug-gmp-warning-letters-0001 50. Unger, B. (2018). An analysis of 2017 FDA warning letters on Data Integrity. Pharmaceutical Online. 51. USFDA Inspection citation data base, Inspection Observations, Available Form: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classificationdatabase 52. USFDA 21 CFR Part 211. Current Good Manufacturing Practice for Finished Pharmaceuticals. Available Form: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 53. USFDA Code of Federal Regulations (CFR) Title 21, Parts 11, 210, Available Form: Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA 54. USFDA Warning Letters, Available Form: https://www.fda.gov/inspections-compliance-enforcement-andcriminal-investigations/compliance-actions-and-activities/warning-letters 55. Vignesh, M., & Ganesh, G. N. K. (2020). Current status, challenges and preventive strategies to overcome data integrity issues in the pharmaceutical industry. International Journal of Applied Pharmaceutics, 19-23. 56. WHO TRS 986 – Annex 2, Available Form: https://www.who.int/publications/m/item/trs986-annex2 57. WHO TRS 1033 - Annex 4: WHO Guideline on data integrity, Available Form: https://www.who.int/publications/m/item/annex-4-trs-1033 58. Winchell, T. (2011). FDA Warning Letter: Avoidance and Advice. The Quality Assurance Journal, 14(3-4), 7679.